LTR Pharma has received ethics approval for a clinical study of SPONTAN® in pulmonary arterial hypertension (PAH). PAH represents a significant global therapeutics market, estimated at

LTR Pharma Limited (ASX:LTP) has announced that more than 2,000 bottles of SPONTAN®, our rapid-onset intranasal vardenafil spray, have been dispensed in Australia under the

LTR Pharma (ASX: LTP) has confirmed the first patient-specific ROXUS® prescriptions received through Mavrox, Shed’s men’s health telehealth platform, have now been fulfilled in the

At the Asia-Pacific Prostate Cancer Conference (APCC) in Melbourne, Nurse Practitioner and Sexologist Melissa Hadley Barrett presented outcomes from 147 men who used SPONTAN nasal spray with

LTR Pharma has received the final Clinical Study Report for its SPONTAN® Phase II pharmacokinetic study. The report completes the pharmacokinetic dataset agreed with the

LTR Pharma has entered into an exclusive pilot commercialisation agreement with Marius Pharmaceuticals, a US pharmaceutical company focused on men’s health, to introduce Marius’ lead